FLORBETAPIR

DRUG4 trials

Sponsors

Eli Lilly & Co., University of Southern California, Centre Hospitalier Universitaire, Amiens

Conditions

Alzheimer DiseaseAlzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental DisordersAlzheimer's Disease (AD)Cognition DisordersDementiaEarly Mild Cognitive Impairment (EMCI)Late Mild Cognitive Impairment (LMCI)Mild Cognitive Impairment (MCI)

Phase 2

I5T-MC-AACI: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

CompletedCTIS2023-507303-55-00

Eli Lilly & Co.Alzheimer Disease

Start: 2020-09-30End: 2025-09-17Target: 224Updated: 2025-01-23

Phase 3

Cerebral Amyloid Imaging Using Florbetapir (AV-45)

Centre Hospitalier Universitaire, AmiensCognition Disorders, Dementia

Start: 2014-09-30End: 2022-09-30Target: 100Updated: 2018-08-03

I5T-MC-AACO: Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease

RecruitingCTIS2025-522340-40-00

Eli Lilly & Co.Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

Start: 2025-12-04Target: 170Updated: 2026-01-19

Unknown Phase

Alzheimer's Disease Neuroimaging Initiative 2

CompletedNCT01231971

University of Southern CaliforniaAlzheimer's Disease (AD), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI) +2

Start: 2011-02-14End: 2017-11-29Updated: 2024-11-21

Related Papers

Do Amyloid Cerebral Deposits Influence the Long-Term Poststroke Cognitive Outcome?: The IDEA3 Study

Stroke2024-12-094 citations

Self‐reported hearing loss is associated with faster cognitive and functional decline but not diagnostic conversion in the ADNI cohort

Alzheimer s & Dementia2024-09-264 citations

Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis

Alzheimer s & Dementia2024-09-011 citations

A protocol paper for the MOTION Study—A longitudinal study in a cohort aged 60 years and older to obtain mechanistic knowledge of the role of the gut microbiome during normal healthy ageing in order to develop strategies that will improve lifelong health and wellbeing

PLoS ONE2022-11-188 citations

Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition

Journal of Neurology Neurosurgery & Psychiatry2021-06-2969 citations